Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02506959
Recruitment Status : Active, not recruiting
First Posted : July 23, 2015
Last Update Posted : April 29, 2022
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Tracking Information
First Submitted Date  ICMJE July 22, 2015
First Posted Date  ICMJE July 23, 2015
Last Update Posted Date April 29, 2022
Actual Study Start Date  ICMJE September 14, 2015
Estimated Primary Completion Date August 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 26, 2018)
Progression free survival (PFS) [ Time Frame: 1 year ]
Estimated by the Kaplan-Meier method. Comparison of time to event endpoints by subgroups will be made using the log-rank test. Cox proportional hazards regression will be employed for univariate and multivariate analysis on time-to-event outcomes.
Original Primary Outcome Measures  ICMJE
 (submitted: July 22, 2015)
  • Improvement in Progression-Free Survival (PFS) in Participants with Refractory Multiple Myeloma Receiving First Stem Cell Transplant [ Time Frame: 1 year ]
    The 1-year PFS rate in cohort 1 (refractory, 1st transplant) associated with GemBuMel is 62%. With 40 patients in this cohort, assuming exponentially-distributed PFS times, 1.5 years of accrual followed by 2 years of follow-up, and a one-sided 5% Type I error rate, 40 patients provides more than 80% power to detect an increase in one-year PFS to 75% in this cohort. International Myeloma Working Group (IMWG) uniform response criteria used.
  • Improvement in Progression-Free Survival (PFS) in Participants with Relapsed Multiple Myeloma Receiving Second Salvage Stem Cell Transplant [ Time Frame: 1 year ]
    In cohort 2 (2nd transplant), the historical 1-year PFS rate is 55%. Under the same assumptions, 40 patients will provide more than 80% power to detect an increase in 1-year PFS to 69%. International Myeloma Working Group (IMWG) uniform response criteria used.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 13, 2019)
  • Complete response (CR) rate [ Time Frame: By day 100 ]
    Assessed using the International Myeloma Working Group (IMWG) uniform response criteria. Reported along with corresponding 95% confidence intervals. Logistic regression will be used to model the association between response rates and prognostic factors.
  • Overall survival (OS) [ Time Frame: Up to 2 years ]
    Estimated by the Kaplan-Meier method. Comparison of time to event endpoints by subgroups will be made using the log-rank test. Cox proportional hazards regression will be employed for univariate and multivariate analysis on time-to-event outcomes.
  • Complete response (CR) + very good partial response (VGPR) rate [ Time Frame: By day 100 ]
    Assessed using the International Myeloma Working Group (IMWG) uniform response criteria. Reported along with corresponding 95% confidence intervals. Logistic regression will be used to model the association between response rates and prognostic factors.
  • Response rate [ Time Frame: By day 100 ]
    Assessed using the International Myeloma Working Group (IMWG) uniform response criteria. Reported along with corresponding 95% confidence intervals. Logistic regression will be used to model the association between response rates and prognostic factors.
  • Minimal residual disease post-transplant [ Time Frame: Up to 2 years ]
    Minimal residual disease post-transplant will be measured by multiparametric flow cytometry.
  • Incidence of grade 3 or greater side effects [ Time Frame: Up to day 100 ]
    Assessed according to Common Terminology Criteria for Adverse Events version 4.0. The treatment-related morality rate will be computed and presented with 95% confidence interval. Adverse events will be tabulated for all patients.
  • Predictive value of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio, and Myc [ Time Frame: Up to 2 years ]
    Correlation with PFS and OS of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio and Myc will be analyzed using the log-rank test. The correlation with CR, VGPR+CR and RR of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio, and Myc will be analyzed using Fisher's F test.
  • Prognostic effect of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio, and Myc [ Time Frame: Up to 2 years ]
    Correlation with PFS and OS of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio and Myc will be analyzed using the log-rank test. The correlation with CR, VGPR+CR and RR of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio, and Myc will be analyzed using Fisher's F test.
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
Official Title  ICMJE Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma
Brief Summary This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplant work in treating patients with multiple myeloma that does not respond to treatment (refractory) or has returned (relapsed). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving high-dose chemotherapy, such as gemcitabine hydrochloride, busulfan, and melphalan, before a peripheral blood stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Previously collected stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
Detailed Description

PRIMARY OBJECTIVES:

I. To determine the progression-free survival (PFS) in patients with refractory or relapsed myeloma receiving panobinostat/gemcitabine hydrochloride (gemcitabine)/busulfan/melphalan (panobinostat/Gem/Bu/Mel) with autologous stem-cell transplant, either as a first or a salvage stem-cell transplant.

SECONDARY OBJECTIVES:

I. To evaluate the complete response (CR) rate. II. To determine the overall survival (OS). III. To determine the CR + very good partial remission (VGPR) rate. IV. To determine the overall response rate (ORR). V. To determine minimal residual disease posttransplant, measured by multiparametric flow cytometry (MFC).

VI. To describe the toxicity profile of panobinostat/Gem/Bu/Mel. VII. To analyze the predictive value of pretransplant levels in myeloma cells of X-box binding protein 1 (XBP1), inositol-requiring enzyme 1 (IRE1), unspliced XBP1 (XBP1u), sliced XBP1 (XPB1s), XBP1u/XPBs ratio and v-myc myelocytomatosis viral oncogene homolog (avian) (Myc), by analyzing their correlation with CR, VGPR+CR and response rate (RR).

VIII. To study the prognostic effect of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio and Myc, by analyzing their correlation with PFS and OS.

OUTLINE:

Patients receive panobinostat orally (PO) once daily (QD) on days -9 to -2, gemcitabine hydrochloride intravenously (IV) over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.

After completion of study treatment, patients are followed up at 1 month, 100 days, 6 months, 1 year, and then every 3-6 months for at least 2 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Plasma Cell Leukemia
  • Plasmacytoma
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
Intervention  ICMJE
  • Procedure: Autologous Hematopoietic Stem Cell Transplantation
    Undergo autologous peripheral blood stem cell transplant
    Other Names:
    • AHSCT
    • Autologous
    • Autologous Hematopoietic Cell Transplantation
    • Autologous Stem Cell Transplant
    • Autologous Stem Cell Transplantation
    • Stem Cell Transplantation, Autologous
  • Drug: Busulfan
    Given IV
    Other Names:
    • 1, 4-Bis[methanesulfonoxy]butane
    • BUS
    • Bussulfam
    • Busulfanum
    • Busulfex
    • Busulphan
    • CB 2041
    • CB-2041
    • Glyzophrol
    • GT 41
    • GT-41
    • Joacamine
    • Methanesulfonic Acid Tetramethylene Ester
    • Methanesulfonic acid, tetramethylene ester
    • Mielucin
    • Misulban
    • Misulfan
    • Mitosan
    • Myeleukon
    • Myeloleukon
    • Myelosan
    • Mylecytan
    • Myleran
    • Sulfabutin
    • Tetramethylene Bis(methanesulfonate)
    • Tetramethylene bis[methanesulfonate]
    • WR-19508
  • Drug: Gemcitabine Hydrochloride
    Given IV
    Other Names:
    • dFdCyd
    • Difluorodeoxycytidine Hydrochloride
    • FF 10832
    • FF-10832
    • FF10832
    • Gemcitabine HCI
    • Gemzar
    • LY-188011
    • LY188011
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Drug: Melphalan
    Given IV
    Other Names:
    • Alanine Nitrogen Mustard
    • CB-3025
    • L-PAM
    • L-Phenylalanine Mustard
    • L-Sarcolysin
    • L-Sarcolysin Phenylalanine mustard
    • L-Sarcolysine
    • Melphalanum
    • Phenylalanine Mustard
    • Phenylalanine Nitrogen Mustard
    • Sarcoclorin
    • Sarkolysin
    • WR-19813
  • Drug: Panobinostat
    Given PO
    Other Names:
    • Faridak
    • LBH589
  • Procedure: Peripheral Blood Stem Cell Transplantation
    Undergo autologous peripheral blood stem cell transplant
    Other Names:
    • PBPC transplantation
    • PBSCT
    • Peripheral Blood
    • Peripheral Blood Progenitor Cell Transplantation
    • PERIPHERAL BLOOD STEM CELL TRANSPLANT
    • Peripheral Stem Cell Support
    • Peripheral Stem Cell Transplant
    • Peripheral Stem Cell Transplantation
  • Other: Pharmacological Study
    Correlative studies
Study Arms  ICMJE Experimental: Treatment (panobinostat, Gem/Bu/Mel, ASCT)
Patients receive panobinostat PO QD on days -9 to -2, gemcitabine hydrochloride IV over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.
Interventions:
  • Procedure: Autologous Hematopoietic Stem Cell Transplantation
  • Drug: Busulfan
  • Drug: Gemcitabine Hydrochloride
  • Other: Laboratory Biomarker Analysis
  • Drug: Melphalan
  • Drug: Panobinostat
  • Procedure: Peripheral Blood Stem Cell Transplantation
  • Other: Pharmacological Study
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: April 22, 2022)
83
Original Estimated Enrollment  ICMJE
 (submitted: July 22, 2015)
80
Estimated Study Completion Date  ICMJE August 1, 2022
Estimated Primary Completion Date August 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Refractory or relapsed myeloma, defined as one or more of the following:

    • Treated with first-line therapy including at least 2 cycles of lenalidomide, bortezomib or thalidomide, and one or more of the following:

      • Less than partial response (PR) to first-line therapy
      • Relapse after first (1st) line therapy
    • High-risk cytogenetics, defined by deletion (del)(13q) by conventional cytogenetics, or by del(17p), t(4;14), t(14;16), t(14;20) or 1q+ by fluorescence in situ hybridization (FISH)
    • Relapse after a prior autologous stem cell transplant (ASCT)
    • Plasma cell leukemia
    • Soft tissue plasmacytoma
  • Serum creatinine =< 1.8 mg/dL and/or estimated serum creatinine clearance >= 50 ml/min
  • Serum glutamic oxaloacetic transaminase (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) =< 3 x upper limit of normal
  • Serum bilirubin =< 2 x upper limit of normal, unless proven to be due to disease involvement
  • Alkaline phosphatase =< 2 x upper limit of normal, unless proven to be due to disease involvement
  • Adequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volume
  • Adequate cardiac function with left ventricular ejection fraction >= 40%
  • No uncontrolled arrhythmias or symptomatic cardiac disease
  • Clinically euthyroid; note: patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism
  • Zubrod performance status < 2
  • Negative beta-human chorionic gonadotropin (HCG) test in a woman of child-bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization
  • Availability of >= 2.5 million cluster of differentiation (CD)34+ cells/kg previously apheresed
  • Ability to provide written informed consent

Exclusion Criteria:

  • Prior whole brain irradiation
  • Having received radiation therapy to head and neck (excluding eyes), and internal organs of chest, abdomen or pelvis in the month prior to enrollment
  • Active hepatitis B, either active carrier (hepatitis B surface antigen positive [HBsAg +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)
  • Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
  • Active infection requiring parenteral antibiotics
  • Known positivity for human immunodeficiency virus (HIV)
  • Autologous stem-cell transplant in the previous six months
  • Needing valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatment
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
  • Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol
  • Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:

    • History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible but should be discussed with Secura Bio, Inc (Secura Bio) prior to enrollment)
    • Any history of ventricular fibrillation or torsade de pointes
    • Bradycardia defined as heart rate (HR) < 50 beats per minute (bpm); patients with pacemakers are eligible if HR >= 50 bpm
    • Screening electrocardiogram (ECG) with a corrected QT (QTc) > 470 msec
    • Right bundle branch block + left anterior hemiblock (bifascicular block)
    • Myocardial infarction or unstable angina =< 12 months prior to starting study drug
    • Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
  • Have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  • Prior malignancy with in the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
  • Any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff
  • Received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
  • Having received immunotherapy or chemotherapy within 2 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
  • Grade >= 3 nonhematological toxicity from prior therapy that has not resolved to =< grade 1
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02506959
Other Study ID Numbers  ICMJE 2014-0516
NCI-2015-01308 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2014-0516 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party M.D. Anderson Cancer Center
Original Responsible Party Same as current
Current Study Sponsor  ICMJE M.D. Anderson Cancer Center
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: Yago L Nieto M.D. Anderson Cancer Center
PRS Account M.D. Anderson Cancer Center
Verification Date April 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP